Repository logo
Log In
  1. Home
  2. Unibas
  3. Publications
  4. The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days
 
  • Details

The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days

Date Issued
2020-01-01
Author(s)
Janiaud, Perrine  
Axfors, Cathrine
Van't Hooft, Janneke
Saccilotto, Ramon  
Agarwal, Arnav
Appenzeller-Herzog, Christian  
Contopoulos-Ioannidis, Despina G.
Danchev, Valentin
Dirnagl, Ulrich
Ewald, Hannah  
Gartlehner, Gerald
Goodman, Steven N.
Haber, Noah A.
Ioannidis, Angeliki Diotima
Ioannidis, John P. A.
Lythgoe, Mark P.
Ma, Wenyan
Macleod, Malcolm
Malički, Mario
Meerpohl, Joerg J.
Min, Yan
Moher, David
Nagavci, Blin
Naudet, Florian
Pauli-Magnus, Christiane  
O'Sullivan, Jack W.
Riedel, Nico
Roth, Jan A.  
Sauermann, Mandy  
Schandelmaier, Stefan  
Schmitt, Andreas M.  
Speich, Benjamin  
Williamson, Paula R.
Hemkens, Lars G.  
DOI
10.12688/f1000research.26707.1
Abstract
Background; : Never before have clinical trials drawn as much public attention as those testing interventions for COVID-19. We aimed to describe the worldwide COVID-19 clinical research response and its evolution over the first 100 days of the pandemic.; Methods:; Descriptive analysis of planned, ongoing or completed trials by April 9, 2020 testing any intervention to treat or prevent COVID-19, systematically identified in trial registries, preprint servers, and literature databases. A survey was conducted of all trials to assess their recruitment status up to July 6, 2020.; Results:; Most of the 689 trials (overall target sample size 396,366) were small (median sample size 120; interquartile range [IQR] 60-300) but randomized (75.8%; n=522) and were often conducted in China (51.1%; n=352) or the USA (11%; n=76). 525 trials (76.2%) planned to include 155,571 hospitalized patients, and 25 (3.6%) planned to include 96,821 health-care workers. Treatments were evaluated in 607 trials (88.1%), frequently antivirals (n=144) or antimalarials (n=112); 78 trials (11.3%) focused on prevention, including 14 vaccine trials. No trial investigated social distancing. Interventions tested in 11 trials with >5,000 participants were also tested in 169 smaller trials (median sample size 273; IQR 90-700). Hydroxychloroquine alone was investigated in 110 trials. While 414 trials (60.0%) expected completion in 2020, only 35 trials (4.1%; 3,071 participants) were completed by July 6. Of 112 trials with detailed recruitment information, 55 had recruited <20% of the targeted sample; 27 between 20-50%; and 30 over 50% (median 14.8% [IQR 2.0-62.0%]).; Conclusions:; The size and speed of the COVID-19 clinical trials agenda is unprecedented. However, most trials were small investigating a small fraction of treatment options. The feasibility of this research agenda is questionable, and many trials may end in futility, wasting research resources. Much better coordination is needed to respond to global health threats.
File(s)
Loading...
Thumbnail Image
Name

20201022090834_5f912ff22dec8.pdf

Size

1.56 MB

Format

Adobe PDF

Checksum

(MD5):54c2542140a03c1a4efd577a1003227b

University of Basel

edoc
Open Access Repository University of Basel

  • About edoc
  • About Open Access at the University of Basel
  • edoc Policy

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement